PACB Jan 2023 45.000 call
| Previous Close | 1.6500 |
| Open | 1.6500 |
| Bid | 1.0000 |
| Ask | 2.6500 |
| Strike | 45.00 |
| Expire Date | 2023-01-20 |
| Day's Range | 1.6500 - 1.6500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 42 |
- GlobeNewswire
Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer
Genomics Veteran to Lead Company Which Has a Commercial-Ready Novel Technology Platform that Can Realize the Largely Untapped Contribution of Epigenetics to Human Health Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer Genomics Veteran to Lead Company Which Has a Commercial-Ready Novel Technology Platform that Can Realize the Largely Untapped Contribution of Epigenetics to Human Health CAMBRIDGE, United Kingdom, June 14, 2022 (GLOBE NEWSWIRE) -- Cambridge Epigenetix (CEGX), a l
- Simply Wall St.
Pacific Biosciences of California (NASDAQ:PACB) dips 18% this week as increasing losses might not be inspiring confidence among its investors
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
- GlobeNewswire
PacBio Collaborates with iLAC and Robotic Biology Institute to Develop Automated Workflows
Advanced Automation Aims to Optimize Service Lab Efficiency and Highly Reproducible Data Production from HiFi Long-Read SequencingMENLO PARK, Calif., TOKYO, May 09, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration with genome analysis company iLAC, Inc. (iLAC) and Robotic Biology Institute, Inc. (RBI) to develop fully automated end-to-end workflows for PacBio’s Sequel II and Sequel IIe HiFi
